Abstract
Objective To evaluate the efficacy and safety of cyclophosphamide in the treatment of patients with myasthenia gravis (MG) and thymoma. Methods Ninety-five MG patients with thymoma were selected, and 60 of them were finally involved in the study. Patients were given low or median dose of cyclophosphamide (0.20 g intravenously per day, twice a week), and the dose was gradually increased to 0.80 g intravenously per week. When the total dose of cyclophosphamide reached 6 and 10 g, the drug efficacy was respectively assessed by Clinical Absolute Score (CAS) and Clinical Relative Score (CRS). Adverse events were also recorded. Results Compared with the score before treatment (19.65 ± 8.90), the CAS after 6 g (13.73 ± 8.63) and 10 g (10.58 ± 8.11) cyclophosphamide treatment were significantly lower than that of before treatment ( P < 0.05, for all). The drug efficacy of the treatment was 73.33% (44/60) and 81.67% (49/60) when the total dose reached 6 and 10 g, respectively. No serious adverse reactions occurred. Conclusions Cyclophosphamide is an effective and safe treatment for post-thymectomized patients with myasthenia gravis and thymoma. Further follow-up and study is still needed to evaluate the long-term outcome. doi: 10.3969/j.issn.1672-6731.2014.10.010
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
More From: Chinese Journal of Contemporary Neurology and Neurosurgery
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.